Sanofi and Johnson & Johnson's Janssen Pharmaceuticals have announced a collaboration to jointly develop and commercialize a vaccine candidate targeting extraintestinal pathogenic Escherichia coli (E. coli), which is responsible for bacterial infections.
Partnership Details
Under the agreement, Sanofi will make an upfront payment of $175 million to Janssen, the developer of the vaccine. Additionally, both companies will share the costs of current and future research and development. Sanofi and Janssen will also share the profits generated by the vaccine in the United States, France, Germany, Italy, Spain, and the United Kingdom. In the rest of the world, Janssen will receive tiered royalties and sales milestones.
Advancing Clinical Trials
The vaccine is currently undergoing a late-stage clinical trial, initiated by Janssen in 2021. The trial is actively enrolling patients, with the aim to further evaluate the efficacy and safety of the vaccine.
Addressing Antimicrobial Resistance
Extraintestinal pathogenic E. coli plays a significant role in driving antimicrobial resistance. By developing a vaccine against this pathogen, Sanofi aims to combat the increasing threat of bacterial infections.
